Amoxicillin Sodium

證據等級: L5

預測適應症: 0 個

Amoxicillin Sodium: Antibiotic — Repurposing Evaluation Incomplete

One-Sentence Summary

Amoxicillin Sodium is a widely used broad-spectrum β-lactam antibiotic registered in Malaysia under 5 product licenses. The current Evidence Pack did not generate any TxGNN repurposing predictions due to missing critical data inputs — key data gaps including package insert warnings and mechanism of action must be resolved before a meaningful evaluation can proceed. Until these gaps are addressed, no evidence level can be assigned and a Hold decision is recommended.

Quick Overview

Item	Content
Original Indication	Unavailable (license text not populated in Evidence Pack)
Predicted New Indication	None — no predictions generated
TxGNN Prediction Score	N/A
Evidence Level	N/A — below L5 (no predictions produced)
Malaysia Market Status	✓ Marketed
Number of Registrations	5
Recommended Decision	Hold

Why is This Prediction Reasonable?

No predicted indications were generated in this Evidence Pack — the predicted_indications array is empty. This means the TxGNN pipeline did not produce any repurposing candidates for Amoxicillin Sodium under the current data configuration, and a standard mechanism-to-new-indication analysis cannot be performed.

Currently, detailed mechanism of action data is not available. Based on established pharmacological knowledge, Amoxicillin Sodium belongs to the aminopenicillin subgroup of β-lactam antibiotics, with its primary mechanism involving inhibition of bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). However, this information was not confirmed via DrugBank in the current Evidence Pack, and therefore cannot be formally relied upon for mechanism-of-action mapping within the TxGNN framework.

To unlock repurposing candidates, three inputs must first be in place: a confirmed DrugBank ID linked to Amoxicillin Sodium, populated approved indication text from NPRA license records, and resolved package insert data to pass the safety pre-screen. Once these are available, re-running the Knowledge Graph and Deep Learning prediction steps should produce meaningful candidates.

Clinical Trial Evidence

Currently no related clinical trials registered in this Evidence Pack.

Literature Evidence

Currently no related literature available in this Evidence Pack.

Malaysia Market Information

Five product registrations were identified via NPRA query (query date: 2026-03-27) and the query was logged as successful (result_count: 5). However, all detailed license fields — license number, product name, dosage form, manufacturer, and approved indication text — were returned as empty strings, suggesting a data parsing or field-mapping issue downstream of the API call rather than a true absence of registrations.

Authorization Number	Product Name	Dosage Form	Approved Indication
(Not populated)	(Not populated)	(Not populated)	(Not populated)
(Not populated)	(Not populated)	(Not populated)	(Not populated)
(Not populated)	(Not populated)	(Not populated)	(Not populated)
(Not populated)	(Not populated)	(Not populated)	(Not populated)
(Not populated)	(Not populated)	(Not populated)	(Not populated)

Action required: The NPRA returned 5 records but field mapping failed. Re-run the data parsing pipeline against the raw NPRA response to repopulate these rows before downstream analysis.

Safety Considerations

Please refer to the package insert for safety information.

Note: Both key warnings and contraindications carry outstanding data gaps at Blocking severity (DG001), which prevents safety pre-screening from proceeding. No drug-drug interaction records were identified (DDI query returned 0 results). Safety evaluation is fully blocked until package insert data is retrieved from the NPRA official source and parsed.

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN repurposing predictions were generated and two critical data gaps — a Blocking-severity gap on package insert warnings and a High-severity gap on mechanism of action — prevent both safety pre-screening and mechanism-of-action analysis. This evaluation cannot advance until the gaps below are resolved.

To proceed, the following is needed:

[DG001 — Blocking] Download and parse the package insert PDF from the NPRA official website to extract warnings, precautions, and contraindications for Amoxicillin Sodium
[DG002 — High] Query the DrugBank API to confirm the DrugBank ID and retrieve full MOA data; a confirmed ID is a prerequisite for KG-based prediction
[License data repopulation] Investigate why the 5 NPRA-registered product records returned with all empty fields; inspect the raw API response and fix the field-mapping logic in the data processing pipeline
[Re-run TxGNN pipeline] Once DrugBank ID is confirmed and indication text is available, re-execute run_kg_prediction.py and txgnn_model.py to generate repurposing candidates
[Evidence collection] After predictions are generated, run ClinicalTrials.gov and PubMed collectors against the top-ranked predicted indication to build an evidence table and assign a formal evidence level (L1–L5)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.